活血化瘀对肺心病急性发作期治疗的理论及研究

Theory and Research on Pulmonary Heart diseaseTreatment on the Stage of Acute Attack withBlood-activating and Stasis-dissolving

目的:观察活血化瘀药天保康注射液对肺心病急性期疗效有无提高。方法:随机分为天保康治疗组及常规治疗对照组,观察治疗前后肺功能、血气分析、血液流变学及心电图变化。结果:天保康治疗组总有效率为91.1％,常规治疗组有效率为57.0％。结论:活血化瘀药天保康能明显提高肺心病急性加重期的疗效。

Objective: to observe whether or not Tianbaokang injecta, a medicine of blood-activating and stasis-dissolving, can promote the pulmonary heart disease treatment on the stage of acute attack. Method: to divide into Tianbaokang group and normal control group, and to observe the changes of pulmonary function, blood gas analysis, blood rheology and electrocardiogram (ECG) before and after treatment. Results: the effective rate of Tianbaokang group was 91.1% , and the rate of normal control group was 57.0% . Conclusion: the blood-activating and stasis-dissolving medicine---Tianbaokang can obviously promote the pulmonary heat disease curative effect on the stage of acute attack.